Early, Noninvasive Clinical Indicators of Kidney Prognosis in Primary Nephrotic Syndrome: A Retrospective Exploratory Study

Table 2

Univariate Cox proportional hazard regression analysis for prediction of the time to 40% reduction in the eGFR.

Clinical parameters		Hazard ratio [95% CI]	value
At baseline
Age	Per 5 years of age	1.33 [0.93–1.91]	0.120
Sex	Male: 0, female: 1	0.28 [0.03–2.49]	0.252
Kidney tissue diagnosis	MCNS: 0, non-MCNS: 1	2.18 [0.23–20.37]	0.495
u-PCR	Per 1.0 g/gCr	0.96 [0.80–1.16]	0.685
Selectivity index	<0.2 : 0, ≥0.2 : 1	1.81 [0.30–10.91]	0.516
u-suPAR	Per 500 pg/mgCr	1.04 [0.82–1.33]	0.732
u-L-FABP	Per 1.0 μg/gCr	1.00 [1.00–1.01]	0.718
eGFR	Per 10 mL/min/1.73 m^2	0.86 [0.60–1.24]	0.425
s-Albumin	Per 1.0 g/dL	3.39 [0.43–27.02]	0.248
Total cholesterol	Per 10 mg/dL	0.92 [0.81–1.05]	0.214
s-suPAR	Per 500 pg/mL	1.17 [0.98–1.40]	0.081
Cyclosporine use in initial treatment	Nonuse: 0, use: 1	0.29 [0.05–1.83]	0.189
Change (Δ) during 2 months after initiating IST
Δu-PCR (2M)	Per 1.0 g/gCr	1.16 [0.91–1.47]	0.227
Δu-suPAR (2M)	Per 500 pg/mgCr	1.34 [0.92–1.97]	0.130
Δu-L-FABP (2M)	Per 1.0 μg/gCr	1.00 [0.99–1.01]	0.994
ΔeGFR (2M)	Per 10 mL/min/1.73 m^2	0.82 [0.44–1.53]	0.523
Δs-suPAR (2M)	Per 500 pg/mL	1.36 [1.09–1.69]	0.006
At 2 months after initiating IST
u-PCR (2M)	Per 1.0 g/gCr	2.94 [1.43–6.03]	0.003
u-suPAR (2M)	Per 500 pg/mgCr	1.20 [1.00–1.44]	0.050
u-L-FABP (2M)	Per 1.0 μg/gCr	1.14 [1.04–1.26]	0.006
eGFR (2M)	Per 10 mL/min/1.73 m^2	0.79 [0.54–1.15]	0.215
s-suPAR (2M)	Per 500 pg/mL	1.13 [1.03–1.23]	0.015

MCNS, minimal-change nephrotic syndrome; s-, serum; u-, urinary; PCR, protein-to-creatinine ratio; suPAR, soluble urokinase plasminogen activator receptor; L-FABP, liver-type fatty acid-binding protein; eGFR, estimated glomerular filtration rate; IST, immunosuppressive therapy; 95% CI, confidence interval.